

**Owens & Minor - Rotech Investor Presentation**



## Rotech – Investor Presentation

July 23, 2024

Confidential & Proprietary to Owens & Minor, Inc. © 2024 Owens & Minor, Inc.

## Disclaimer

This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This presentation contains certain "forward-looking" statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Some of these statements can be identified by terms and phrases such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These statements include, but are not limited to, statements regarding the proposed transaction with Rotech Healthcare Holdings, Inc. ("Rotech") and opportunities related thereto, Owens & Minor's ("Owens & Minor's" or the "Company's") expectations with respect to its financial performance and expectations of its business. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected, targeted or contemplated in the forward-looking statements, including the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement relating to the proposed transaction; risks related to disruption of management's attention from Owens & Minor's ongoing business operations due to the proposed transaction; the effect of the announcement of the proposed transaction on Owens & Minor's or Rotech's relationships with its customers, suppliers and other third parties, as well as operating results and their businesses generally; the risk that the proposed transaction will not be consummated in a timely manner or at all; exceeding the expected costs of the transaction; the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected and the risk that the combined company may be unable to achieve synergies or it may take longer than expected to achieve those synergies. Investors should refer to Owens & Minor's Annual Report on Form 10-K for the year ended December 31, 2023, including the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the actual results to differ materially from those projected, targeted or contemplated in the forward-looking statements. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, as a result of new information, future developments or otherwise.

This presentation includes certain combined financial information which reflects the sum of the relevant financial information for the Company and Rotech without any other adjustments and refer to such presentation as on a "pro forma" basis for the applicable period. This combination does not comply with U.S. GAAP or with the rules for pro forma presentation. As a result, the combined financial information included in this presentation may differ from pro forma financial information prepared in accordance with U.S. GAAP and the rules and regulations of the SEC, and any such differences could be material.

Certain financial measures included herein are not made in accordance with U.S. GAAP, including Adjusted EBITDA and Adjusted EPS, and use of such terms varies from others in the same industry. Management uses these non-GAAP financial measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Non-GAAP financial measures should not be considered as alternatives to measures derived in accordance with U.S. GAAP. Non-GAAP financial measures have important limitations as analytical tools and you should not consider them in isolation or as substitutes for results as reported in accordance with U.S. GAAP. Projected or targeted GAAP financial measures and reconciliations of projected or targeted non-GAAP financial measures are not provided herein because such GAAP financial measures are not available on a forward-looking basis and such reconciliations could not be derived without unreasonable effort.

Note: To be updated to reflect final presentation.

Owens & Minor uses its web site, [www.owens-minor.com](http://www.owens-minor.com), as a channel of distribution for material Company information, including news releases, investor presentations and financial information. This information is routinely posted and accessible under the Investor Relations section.

# Transaction Overview



## Key Stats

- Purchase price of \$1.36 billion in cash or \$1.32 billion net of tax benefits<sup>(1)</sup>
- 6.3x implied LTM EBITDA multiple<sup>(1)</sup>
- 5.1x implied synergized<sup>(2)</sup> LTM EBITDA multiple<sup>(1)</sup>
- Expected close in 2024<sup>(3)</sup>



## Strategic Rationale

- Improves Patient Direct capabilities
- Expands reach across an integrated national network
- Enables Owens & Minor to achieve improved service to patients, providers, and payors



## Financial Implications

- Accelerates top line and earnings growth
- Adjusted EPS neutral in year 1 and approximately \$0.15 accretion in year 2
- Expected book leverage at close of ~4.2x; Committed to deleveraging to below 3.0x in approximately 24 months after closing



## 2024 Update

- Q2 2024 revenue of \$2.65 - \$2.67 billion, net loss of \$(35) - \$(32) million, adjusted net income of \$25 - \$28 million, adjusted EBITDA of \$123 - \$127 million, net loss per share of \$(0.46) - \$(0.42), and adjusted EPS of \$0.32 - \$0.36<sup>(4)</sup>
- Company reaffirms full year 2024 outlook for revenue of \$10.5 - \$10.9 billion, Adjusted EBITDA of \$550 - \$590 million and Adjusted EPS of \$1.40 - \$1.70<sup>(5)</sup>

(1) Includes estimated cash tax benefits to Owens & Minor of at least \$40 million.

(2) Assumed run-rate synergies of \$50 million.

(3) Subject to customary approvals and closing conditions.

(4) Reconciliations of the differences between the non-GAAP financial measures presented herein and their most comparable GAAP financial measures are included in the Appendix of this document.

(5) Excludes the impact of Retech transaction.

# Compelling Strategic Rationale and Value Creation Opportunity

## Strategic Rationale



**Strengthens Patient Direct by expanding product offerings through expansion** across complementary portfolios and provides access to the Durable Medical Equipment (DME) market, including hospital beds, wheelchairs, and mobility aids



**Supports combined customer base** allowing Owens & Minor to better serve providers and payors across an integrated national network



**Enables Owens & Minor to more comprehensively serve patients** through the combined suite of product offerings and improved service for patients with chronic conditions in large and fragmented markets



**Provides significant synergy opportunity of approximately \$50 million by the end of year three**, with further upside potential, as well as prospect for additional revenue synergies in both the near and long term

## Value Creation



Accelerates long-term revenue growth



Accretive to operating and EBITDA margins



Improves free cash flow generation



Accretive to Adjusted EPS

## Rotech at-a-Glance

### Proven Track Record

- Best-in-class Home Medical Equipment distributor
- Partner of choice for many payors, providers, suppliers and patients
- 40+ years in operation led by a seasoned management team with 100+ years of combined experience

### Compelling Geographic Footprint

- Robust and scalable national infrastructure
- Reliable national delivery across approximately 325 locations in 46 states

### Comprehensive Product Portfolio

- Focused on high growth end markets for patients with chronic conditions
- Diversified mix across patients, suppliers, payors and geographic footprint
- Extensive product offerings

**ROTECH**  
HEALTHCARE INC.  
Key Stats

 **~\$750mm**  
2023A Net Revenue

 **\$200mm+**  
2023A Adj. EBITDA

 **Above Market**  
Organic Revenue CAGR

 **4,200+**  
Employees


 **300+**  
Account Executives

**GM** Genentech  
& Mirco

8 | Confidential & Proprietary to Genentech & Mirco, Inc.

# Rotech Further Diversifies our Patient Direct Business


2023A Pro Forma Patient Direct Business Mix



Key Business Mix Takeaway

*Rotech enhances Patient Direct's diversified product portfolio*

2023A Pro Forma Patient Direct Payor Mix



Key Payor Mix Takeaway

*Rotech shifts Patient Direct's payor mix slightly away from commercial payors toward government*

8 | Confidential & Proprietary to Covidien & Medtronic, Inc. (1) Includes Other Medical Supplies, Other Equipment and Services, DME / Other and Capitalized Arrangements. (2) Includes Patient Pay.





# Alignment with Our Patient Direct Vision

Framing the 2028 Patient Direct Vision Presented at Investor Day

## Patient Direct

Strong brand recognition with a national footprint and local presence



Proven model is expected to continue to drive organic growth



Expansive opportunities to serve patients across core disease categories and numerous opportunities to enter adjacencies



Focus investments to drive organic growth



Rotech Advances the Patient Direct 2028 Vision



Revenue of \$5 billion or more



Revenue CAGR of 8%+



Adjusted Operating Income Target of \$400 million+

7 | Confidential & Proprietary to Otsuka & Mirco, Inc.



---

## Financial Implications

---

<b>Sales &amp; Growth</b>	<ul style="list-style-type: none"><li>• Further scales business and accelerates company long-term growth rate</li><li>• Ability to leverage sizable combined network with ~625 locations</li></ul>
<b>Earnings &amp; Returns</b>	<ul style="list-style-type: none"><li>• Accretive to operating and EBITDA margins</li><li>• Improves Owens &amp; Minor free cash flow generation</li><li>• Adjusted EPS neutral in year 1 and approximately \$0.15 accretion in year 2</li></ul>
<b>Synergies</b>	<ul style="list-style-type: none"><li>• Expected approximately \$50 million synergy opportunity by the end of year three, with potential for further upside</li><li>• Cost synergies through procurement and DS&amp;A and network consolidation</li></ul>
<b>Deleveraging &amp; Capital Allocation</b>	<ul style="list-style-type: none"><li>• Expected book leverage at close of ~4.2x</li><li>• Focused on deleveraging below 3.0x in approximately 24 months after close</li><li>• Demonstrates commitment to use balance sheet to effectively execute transformative M&amp;A</li></ul>

8 | Confidential & Proprietary to Owens & Minor, Inc.





## Maintain 2024 Company Outlook & Q2 Preliminary Results

\$ in million, except per share data	2024 Outlook <sup>(1)</sup>
Revenue	\$10,500 - \$10,900
Adjusted EBITDA	\$550 - \$590
Adjusted EPS	\$1.40 - \$1.70


\$ in million, except per share data or when otherwise noted	Selected Preliminary Financial Results for Q2 2024 <sup>(2)</sup>
Revenue	\$2.65 - \$2.67 billion
Operating Income, GAAP	\$16 - \$20
Adj. Operating Income, Non-GAAP	\$72 - \$76
Net Loss, GAAP	\$(35) - \$(32)
Adj. Net Income, Non-GAAP	\$25 - \$28
Adj. EBITDA, Non-GAAP	\$123 - \$127
Net Loss per common share, GAAP	\$(0.46) - \$(0.42)
Adj. Net Income per share, Non-GAAP	\$0.32 - \$0.36
Operating Cash Flow	\$111 - \$116
Total debt and net debt reduction	\$68 - \$71

9 | Confidential & Proprietary to Oetis & Minor, Inc.

<sup>(1)</sup> Excludes the impact of Ritech transaction.  
<sup>(2)</sup> Reconciliation of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are in the tables included herein.



## Summary of Key Investment Highlights



• • • APPENDIX • • •

## GAAP/Non-GAAP Reconciliations

\$ in millions	Three Months Ended June 30, 2024	
	Low	High
Operating income, as reported (GAAP)	\$ 16	\$ 20
Acquisition-related charges and intangible amortization <sup>(1)</sup>	20	20
Exit and realignment charges, net <sup>(2)</sup>	29	29
Litigation and related charges <sup>(3)</sup>	7	7
<b>Operating income, adjusted (non-GAAP) (Adjusted Operating Income)</b>	<b>\$ 72</b>	<b>\$ 76</b>

\$ in millions	Three Months Ended June 30, 2024	
	Low	High
Net loss, as reported (GAAP)	\$ (35)	\$ (32)
Pre-tax adjustments:		
Acquisition-related charges and intangible amortization <sup>(1)</sup>	20	20
Exit and realignment charges, net <sup>(2)</sup>	29	29
Litigation and related charges <sup>(3)</sup>	7	7
Income tax benefit on pre-tax adjustments <sup>(4)</sup>	(13)	(13)
One-time income tax charge <sup>(5)</sup>	17	17
<b>Net income, adjusted (non-GAAP) (Adjusted Net Income)</b>	<b>\$ 25</b>	<b>\$ 28</b>

12 Confidential & Proprietary to Oetis & Minor, Inc. Note: See p.15, "Definitions of Non-GAAP Reconciliation Items", for footnotes.



## GAAP/Non-GAAP Reconciliations (Continued)

	Three Months Ended June 30, 2024	
	Low	High
<b>Net loss per share, as reported (GAAP)</b>	<b>\$ (0.46)</b>	<b>\$ (0.42)</b>
After-tax adjustments:		
Acquisition-related charges and intangible amortization <sup>(1)</sup>	0.19	0.19
Exit and realignment charges, net <sup>(2)</sup>	0.29	0.29
Litigation and related charges <sup>(3)</sup>	0.08	0.08
One-time income tax charge <sup>(5)</sup>	0.22	0.22
<b>Net income per share, adjusted (non-GAAP) (Adjusted EPS)</b>	<b>\$ 0.32</b>	<b>\$ 0.36</b>

## GAAP/Non-GAAP Reconciliations (Continued)

\$ in millions	Three Months Ended June 30, 2024				
		Low		High	
<b>Net loss, as reported (GAAP)</b>	\$		(35)	\$	(32)
Income tax provision			15		16
Interest expense, net			36		36
Acquisition-related charges and intangible amortization <sup>(1)</sup>			20		20
Exit and realignment charges, net <sup>(2)</sup>			29		29
Other depreciation and amortization <sup>(6)</sup>			46		46
Stock compensation <sup>(7)</sup>			6		6
LIFO credits <sup>(8)</sup>			(1)		(1)
Litigation and related charges <sup>(3)</sup>			7		7
<b>Adjusted EBITDA (non-GAAP)</b>	\$		123	\$	127

\$ in millions	June 30, 2024		March 31, 2024			
	Low	High	Low	High		
<b>Total debt, as reported (GAAP)</b>	\$	2,083	\$	2,085	\$	2,154
Cash and cash equivalents		(244)		(244)		(245)
<b>Net debt (non-GAAP)</b>	\$	1,839	\$	1,841	\$	1,909

14 Confidential & Privileged to Oramis & Minor, Inc. Note: See p.15, "Definitions of Non-GAAP Reconciliation Items", for footnotes.





---

## Definitions of Non-GAAP Reconciliation Items

(1) Acquisition-related charges and intangible amortization includes one-time costs related to the expected acquisition of Rotech, including legal and other professional fees, and amortization of intangible assets established during acquisition method of accounting for business combinations. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results.

(2) Exit and realignment charges, net primarily related to our Operating Model Realignment Program, including professional fees, severance, and other costs to streamline functions and processes and costs related to IT strategic initiatives such as converting certain divisions to common IT systems. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis.

(3) Litigation and related charges includes settlement costs and related charges of legal matters within our Apria division. These costs do not occur in the ordinary course of our business and are inherently unpredictable in timing and amount.

(4) These charges have been tax effected by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes.

(5) One-time income tax charge relates to a recent decision associated with Notices of Proposed Adjustments received in 2020 and 2021. The matter at hand, as discussed in previously filed SEC documents, is related to past transfer pricing methodology. We believe the matter will be concluded without further impact to our financial results.

(6) Other depreciation and amortization relates to property and equipment and capitalized computer software, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges.

(7) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges.

(8) LIFO credits includes non-cash adjustments to merchandise inventories valued at the lower of cost or market, with the approximate cost determined by the last-in, first-out (LIFO) method for distribution inventories in the U.S. within our Products & Healthcare Services segment.